Core Insights - Novavax, Inc. will report its third quarter 2025 financial results and operational highlights on November 6, 2025, at 8:30 a.m. ET [1] - The company is focused on tackling global health challenges through its vaccine technology and aims to optimize partnerships and expand its research and development efforts [2] Conference Call Details - The conference call is scheduled for November 6, 2025, at 8:30 a.m. ET, with a registration link provided for participants [1] - Dial-in numbers are available for both U.S. and international participants [1] - A replay of the call will be available starting at 11:30 a.m. ET on November 6, 2025, until November 13, 2025 [2] Company Overview - Novavax specializes in vaccine development, utilizing protein-based nanoparticles and the Matrix-M adjuvant [2] - The company's growth strategy includes optimizing existing partnerships and expanding its technology platform through innovation and collaborations [2]

Q3 2025 Performance Highlights - Q3 2025 sales reached £8,547 million, an increase of 8% [11] - Core operating profit increased by 11% to £2,985 million [11] - Core EPS grew by 14% to 550p [11] - Cash generated from operations year-to-date was £63 billion [11] - The company is on track with its trust rating [11] Guidance Upgrade and Outlook - FY2025 sales growth guidance upgraded from 3-5% to 6-7% [17] - Core OP growth guidance upgraded from 6-8% to 9-11% [17] - Core EPS growth guidance upgraded from 6-8% to 10-12% [17] - The company anticipates sales exceeding £40 billion by 2031 [17] Specialty Medicines Performance - Specialty Medicines sales increased by 16%, driven by Respiratory, Immunology & Inflammation (RI&I), Oncology, and HIV [9] - RI&I sales reached £954 million, with Benlysta up 17% and Nucala up 14% [23, 25] - Oncology sales reached £511 million, with Jemperli up 79% and Ojjaara up 51% [23, 25] - HIV sales reached £1,944 million, driven by long-acting injectables and Dovato [23]

Healthcare Policy & Drug Pricing - Pfizer commits to offering all prescription medications to Medicaid at most favored nation's prices, aiming to significantly reduce Medicaid costs [1] - Pfizer will participate in trumprx.gov, offering discounted treatments for patients not using insurance, but its benefit for insured individuals is questionable [2] - Concerns arise whether trumprx.gov offers something new compared to existing programs like Cost Plus Drugs or direct-to-consumer offerings from pharmaceutical companies [4] - The voluntary nature of the program raises doubts about compliance from other pharmaceutical companies and its long-term viability [5] Vaccine & Public Health - An official is criticized for downplaying the role of vaccines in reducing infectious diseases, particularly polio and rubella [6][7][8] - Experts warn about potential resurgence of eradicated diseases due to misinformation and undermining of vaccine importance [10] - The vast majority of people think vaccines are useful and necessary [12] Government Shutdown Impact on Healthcare - Expiration of Affordable Care Act (ACA) subsidies due to the shutdown could affect 4 million families, potentially doubling their premiums and impacting access to affordable healthcare [13] - Telehealth and in-home care visits, reliant on government funding, are affected by the shutdown [14] - Medicare and Medicaid payment delays to hospitals are expected, potentially leading to staff furloughs and delays in care [15]

Autism Crisis & Prevalence - The report highlights a significant increase in autism rates, from 1 in 10,000 children a few decades ago to 1 in 31 overall, and 1 in 12 for boys in some areas [4][5] - Since 2000, autism rates have surged by more than 400% [5] Potential Causes & Risk Factors - The FDA will notify physicians that acetaminophen (Tylenol) use during pregnancy can be associated with an increased risk of autism [8][9] - The report suggests a potential link between vaccines and autism, advocating for separating the MMR vaccine and delaying the Hepatitis B vaccine until the child is 12 years old [16][18][19] - The report mentions that certain groups, like the Amish, who do not take vaccines or pills, have virtually no autism [7][8] Proposed Actions & Research - HHS is launching an all-agency effort to identify all causes of autism, including toxic and pharmaceutical exposures [27] - NIH will be announcing 13 major grant awards from the autism data science initiatives [21] - The FDA will be updating the label of an existing drug to reflect potential benefits in reducing some autism symptoms [19] Treatment & Prevention - The report suggests that spreading out vaccines over a longer period and in smaller doses may be beneficial [13][14] - The report emphasizes the importance of avoiding Tylenol during pregnancy unless medically necessary [10][11][12]

Welcome back. Mark getting FDA approval for an injectable version of its blockbuster cancer therapy. Kitruda Angelica Peoples here with the story fresh off an interview with the CEO.Angelica. Hey Leslie. Well, MK thinks that this shot will be an attractive option for patients since it could be administered in about a minute in a doctor's office versus 30 minutes at a hospital or an infusion center.And the shot's also a way for Merc to manage the IV form of Kruda going off patent in 2028. And Merc hasn't spe ...

Vaccine Policy & Public Health - A federal panel's new rules for COVID shots could reduce vaccine availability [1] - The Advisory Committee on Immunization Practices (ASIP) recommended that individuals under 65 consult a doctor before receiving the COVID vaccine, differing from previous recommendations for all Americans aged 6 months and older [2] - The panel also voted to restrict the use of the MMRV vaccine, advising against its use for children under four years old [2][3] - Childhood vaccination rates have been declining, leading to nearly 1,500 documented measles cases in the US this year, the highest level in over 25 years [10] Historical Context & Impact of Vaccines - In 1900, the US life expectancy was 473%, significantly lower than today's 784% due to infant and child mortality from preventable diseases [5][6] - Before the introduction of the measles vaccine in the early 1960s, the US saw 3 to 4 million measles cases annually, with 400 to 500 deaths [8] - Measles deaths declined by 90% in the decade after the introduction of measles vaccines, and measles was considered eliminated in the US in 2000 [9] - Vaccines are considered a top innovation for contributing to health, longevity, and overall human well-being [14] Skepticism vs Pseudoscience & Public Trust - The discussion around vaccines is not solely scientific, as panels are now populated with vaccine critics, some of whom have profited from that position [16] - It's important to distinguish legitimate skepticism, which is part of science, from pseudoscience, as public trust and polarization are key issues [17][19] - Herd immunity is crucial, and decreased vaccination rates can affect many people [21][22] - Vaccination is a public health issue and a shared responsibility for the safety and health of the community [22][23]

Epstein案件调查 - 行业关注对Jeffrey Epstein案件的最初调查存在严重缺陷，特别是前劳工部长Alex Acosta在2006年担任美国佛罗里达州南区检察官期间的处理方式[4][7] - 行业观察到Alex Acosta批准的非起诉协议备受争议，该协议使Jeffrey Epstein免受联邦起诉，可能使其免于终身监禁，最终仅以一项州卖淫罪认罪[4] - 行业分析认为，该协议允许Epstein继续性侵和强奸更多年轻女孩，直到2019年因联邦性交易指控被捕[8] - 行业注意到，众议院监督委员会的民主党人表示，Alex Acosta为自己不Prosecute Jeffrey Epstein的决定辩护，并且对自己的行为缺乏悔意[8] - 行业观察到，国会议员Raja Krishna Mory认为，Alex Acosta在Epstein案件中既有不当行为，也有能力不足，因为他没有真正查看受害者的陈述和检查大量证据[22] - 行业关注对Epstein案件的调查可能涉及情报部门的联系，并计划要求中央情报局和情报部门提供有关Epstein的文件[26] - 行业分析认为，需要获取Epstein的财务记录，以了解谁从儿童性交易团伙中受益，以及谁会通过掩盖此事而获利[30] - 行业注意到，参议员Ron Weiden表示，与此儿童性交易团伙相关的电汇交易活动超过10亿美元[30] 言论自由与媒体审查 - 行业关注特朗普政府对第一修正案的战争，包括对媒体的诉讼和威胁[42][45] - 行业注意到，联邦通信委员会（FCC）专员Brendan Carr建议暂停Jimmy Kimmel的节目，随后该节目被无限期停播[46] - 行业分析认为，特朗普政府利用深夜喜剧演员的不合时宜的笑话作为惩罚其不喜欢言论的借口[46] - 行业观察到，NextStar等电视台所有者面临来自特朗普的压力，可能导致其合并受阻[52] 疫苗政策与公共卫生 - 行业关注美国民众对国家卫生机构的信任度下降，特别是对疾病控制与预防中心（CDC）、食品药品监督管理局（FDA）和国家卫生研究院（NIH）的信任度下降[52] - 行业注意到，Robert F Kennedy Jr担任卫生与公众服务部部长后，公众对其提供可靠公共卫生信息的信心较低，仅为39%[52] - 行业关注对儿童疫苗接种计划的潜在修改，包括推迟接种麻疹、腮腺炎、风疹和水痘联合疫苗，以及推迟对婴儿接种乙型肝炎疫苗[53] - 行业专家认为，改变乙型肝炎疫苗的建议并非基于客观全面的数据审查[53] 纽约市长选举 - 行业关注进步派纽约市长候选人Zoran Mandani在初选中意外获胜，为温和派建制派民主党人创造了支持或不支持的选择[54] - 行业注意到，纽约州州长Kathy Hokll正式支持Zoran Mandani，认为他有勇气、紧迫感和乐观精神来领导纽约市应对挑战[54] - 行业观察到，纽约州民主党主席Jay Jacobs明确表示不会支持Zoran Mandani，理由是对以色列和民主社会主义存在根本分歧[54] - 行业分析认为，Zoran Mandani能够赢得不同选民的支持，并有可能与各方合作[55]

Regulatory Changes & Recommendations - The CDC's ACIP committee now recommends individuals consult their doctor to decide on COVID shots, shifting from previous broader recommendations [1] - There are concerns about potential increased restrictions on vaccines in the United States [2][5] - The ACIP committee decided that children under four should receive separate shots for varicella (chickenpox) and MMR instead of the combined MMRV vaccine [3] Committee Composition & Approach - The ACIP committee has a new composition and approach, potentially influenced by Robert F Kennedy Jr [2][7] - Skepticism surrounding the committee's approach to scientific decisions has been validated [9] - The committee is placing increased emphasis on vaccine risks, a departure from previous practices [9] - There are concerns about the experience level of the new ACIP members compared to previous groups [8] Specific Vaccines Under Review - The committee reviewed a combined shot for measles, mumps, rubella, and varicella (MMRV), as well as hepatitis B for newborns, and COVID-19 vaccines [2] - The review of well-established vaccines like MMRV and hepatitis B, without significant new safety data, is considered unusual [6]

Core Insights - Pfizer (PFE) and AstraZeneca (AZN) are leading players in the oncology sector, with significant revenue contributions from this area [1][2] - Pfizer's oncology sales account for over 25% of total revenues, growing by 9% in H1 2025, while AstraZeneca's oncology sales represent around 43% of total revenues, increasing by 16% in the same period [1][2][11] - Both companies have robust R&D pipelines that are expected to drive future growth [3] Pfizer Overview - Pfizer's acquisition of Seagen in 2023 has bolstered its oncology position [4] - Non-COVID operational revenues are improving, with key products generating $4.7 billion in H1 2025, a 15% operational increase year-over-year [5] - Pfizer anticipates $7.7 billion in cost savings by the end of 2027 and projects a revenue CAGR of approximately 6% from 2025 to 2030 [6] - Challenges include potential declines in COVID-related sales and significant patent expirations expected between 2026 and 2030, impacting key products [7][8] AstraZeneca Overview - AstraZeneca's portfolio includes several blockbuster drugs, with sales exceeding $1 billion, contributing to strong revenue growth [9] - The company plans to launch 20 new medicines by 2030, targeting $80 billion in total revenues [12] - AstraZeneca's newer drugs are contributing positively to top-line growth in 2025 [10] - Challenges include the impact of Medicare Part D redesign on key drug sales and competition from generics and biosimilars [13][14] Financial Estimates and Performance - Pfizer's 2025 sales and EPS estimates indicate modest growth of 0.3% and 1.0%, respectively, with EPS estimates rising from $3.05 to $3.14 [15] - AstraZeneca's 2025 sales and EPS estimates suggest stronger growth of 8.4% and 11.4%, with EPS estimates increasing from $4.50 to $4.58 [16] - Year-to-date stock performance shows Pfizer declining by 9.0%, while AstraZeneca has increased by 17.6% [18] Valuation and Dividend Yield - AstraZeneca's shares trade at a forward P/E ratio of 15.44, while Pfizer's are at 7.79, indicating a more attractive valuation for Pfizer [19] - Pfizer offers a higher dividend yield of 7.1% compared to AstraZeneca's 2.4% [22] - AstraZeneca has a higher return on equity at 32.8% versus Pfizer's 21.4% [22] Investment Outlook - Both companies are rated with a Zacks Rank 3 (Hold), making it challenging to determine a clear investment preference [23] - AstraZeneca is viewed as a safer investment due to its efficient profitability and clearer growth targets, despite Pfizer's attractive valuation and dividend yield [25]

Vaccines Are A Hard Business. RFK Jr.’s CDC Is Making It Even Harder https://t.co/79yKBSH5HY ...